Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SMITHKLINE SALT-SPARING DIURETIC, SK&F 101926, IS IN CLINICALS

Executive Summary

SMITHKLINE SALT-SPARING DIURETIC, SK&F 101926, IS IN CLINICALS, the company noted in its recently issued annual report for 1985. An IND for U.S. trials was filed in December 1985. SmithKline said that the drug's initial indication will be for severe water retention conditions. The compound acts on vasopressin, a water-regulating hormone that can control the kidney's water output without depleting salt. The vasopressin antagonist "should also have utility in congestive heart failure," the SmithKline report maintains. SmithKline anticipates the first commercial distribution of the recombinant DNA vaccine for hepatitis B, Energix B, during 1986. The company said that "several trials involving more than 3,000 healthy adults and children show virtually total protection against hepatitis B with a three-dose regimen of Energix B." A second recombinant vaccine under study is a circumsporozite antigen vaccine directed at the most severe form of malaria infection, Plasmodium falciparum. The vaccine is being developed jointly with the U.S. Army's Walter Reed Institute for Research. "We have produced the first vaccine for malaria in quantities large enough for clinical trials," the annual report declares. The trials are expected to begin in 1986.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS009902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel